复合外用药物市场 - 全球产业规模、份额、趋势、机会和预测，按药物类型、按治疗领域、按最终用户、按地区和竞争进行细分，2020-2030 年预测

2024 年全球复方外用药物市场价值为 54.6 亿美元，预计到 2030 年将达到 72.1 亿美元，复合年增长率为 4.72%。复方外用药物可根据患者的个人化需求进行定制，为现成的药物提供替代方案，解决治疗选择的空白。随着医疗保健越来越以患者为中心，对这些药物的需求正在扩大。皮肤病、慢性疼痛管理和荷尔蒙疗法是推动这一成长的关键治疗领域。医生和患者越来越认识到复合药物的价值，因为它在剂量、配方和成分组合方面提供了更大的灵活性。配药药局数量的增加，特别是专注于局部治疗的药局数量，也促进了市场的成长。

市场概况
预测期	2026-2030
2024 年市场规模	54.6 亿美元
2030 年市场规模	72.1 亿美元
2025-2030 年复合年增长率	4.72％
成长最快的领域	疼痛管理
最大的市场	北美洲

有几个因素推动了这一趋势。湿疹、牛皮癣和酒渣鼻等慢性皮肤病的盛行率不断上升，是主要驱动因素。由于这些情况通常需要个人化的治疗方案，复合外用药物可以提供更有效的解决方案来满足特定患者的需求。此外，对疼痛管理的个人化治疗的需求日益增加，特别是局部疼痛缓解。复方外用药物的灵活性允许创造出独特的成分组合，使其能够有效治疗各种各样的疾病。此外，配製技术的进步正在提高这些药物的精确度、品质和安全性，进一步增加其在临床实践中的应用。

儘管复方外用药物市场潜力巨大，但也面临许多挑战。关键问题之一是监管的不确定性。复方药物不像市售药物那样需要经过同样严格的审批程序，这可能会引发人们对产品一致性和安全性的担忧。缺乏标准化引发了有关复方药物监管的争论。此外，受益于规模经济的大量生产药物的竞争，往往会使得复方药物对患者来说更加昂贵。成本因素加上确保品质和遵守法规的复杂性，预计将在未来几年继续对市场构成挑战。

主要市场驱动因素

慢性皮肤病增多

复合技术的进步

更加重视预防保健

主要市场挑战

品质控制和一致性

复合药物成本高

主要市场趋势

转向个人化医疗

疼痛管理解决方案需求增加

分段洞察

药物类型洞察

最终用户洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球复合外用药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类型（荷尔蒙外用药、止痛外用药、抗霉菌及抗菌外用药、皮肤外用药、伤口癒合药、其他）
  • 依治疗领域（疼痛管理、皮肤病和皮肤病学、荷尔蒙治疗、感染、其他）
  • 按最终用户（医院和诊所、药房和零售药局、家庭护理机构、其他）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第 6 章：北美复合外用药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 7 章：欧洲复合外用药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区复合外用药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲复合外用药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲复合外用药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Fresenius Kabi AG
• B. Braun SE
• Hisamitsu Pharmaceutical Co., Inc.
• Glenmark Pharmaceuticals Ltd.
• Optum Inc.
• Nephron Pharmaceuticals Corporation
• Sun Pharmaceutical Industries Ltd.
• Central Admixture Pharmacy Services, Inc.
• CareFirst Specialty Pharmacy
• Medisca Inc.

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Compounded Topical Drug Market was valued at USD 5.46 Billion in 2024 and is expected to reach USD 7.21 Billion in the forecast period with a CAGR of 4.72% through 2030. The Global Compounded Topical Drug Market is experiencing robust growth as patient preferences shift toward personalized and customized healthcare solutions. Compounded topical drugs, which are tailored to meet individual patient needs, offer an alternative to off-the-shelf medications, addressing gaps in treatment options. As healthcare becomes increasingly patient-centric, the demand for these drugs is expanding. Dermatological conditions, chronic pain management, and hormone therapy are among the key therapeutic areas driving this growth. Physicians and patients are increasingly recognizing the value of compounded medications, which provide greater flexibility in dosages, formulations, and combinations of ingredients. The rise in the number of compounding pharmacies, particularly those focusing on topical treatments, is also contributing to market growth.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.46 Billion
Market Size 2030	USD 7.21 Billion
CAGR 2025-2030	4.72%
Fastest Growing Segment	Pain Management
Largest Market	North America

Several factors are driving this trend. The growing prevalence of chronic skin conditions, including eczema, psoriasis, and rosacea, is a major driver. As these conditions often require individualized treatment plans, compounded topical drugs offer solutions that are more effective for specific patient needs. Additionally, there is an increasing demand for personalized treatments in pain management, particularly for localized pain relief. The flexibility of compounded topical drugs allows for the creation of unique combinations of ingredients, making them effective in treating a wide range of conditions. Moreover, advancements in compounding technologies are improving the precision, quality, and safety of these drugs, further increasing their adoption in clinical practice.

Despite its potential, the compounded topical drug market faces several challenges. One of the key issues is regulatory uncertainty. Compounded drugs are not subject to the same stringent approval processes as commercially available drugs, which can raise concerns about the consistency and safety of products. This lack of standardization has led to debates regarding the regulation of compounded medications. Furthermore, competition from mass-produced drugs, which benefit from economies of scale, often makes compounded drugs more expensive for patients. The cost factor, combined with the complexity of ensuring quality and compliance with regulations, is expected to continue posing challenges for the market in the coming years.

Key Market Drivers

Increase in Chronic Skin Conditions

The increase in chronic skin conditions is a significant driver of the Global Compounded Topical Drug Market. Skin disorders such as eczema, psoriasis, acne, and rosacea have seen a rise in prevalence globally due to various factors, including environmental changes, lifestyle habits, genetic predispositions, and an aging population. For instance, atopic dermatitis (AD), a common chronic inflammatory skin disease, affects up to 13% of children and 7% of adults in the United States. These conditions often require long-term management, making conventional over-the-counter treatments less effective or suitable for many patients. As a result, there is a growing demand for customized compounded topical drugs that provide more personalized and targeted solutions for chronic skin conditions.

Compounded topical medications offer the ability to combine multiple active ingredients into a single formulation, which can enhance therapeutic outcomes for patients suffering from skin conditions. For example, a compound may combine anti-inflammatory agents with moisturizers or corticosteroids to treat conditions like eczema or psoriasis more effectively. These tailored treatments cater to the specific needs of patients, whether it's adjusting the concentration of an active ingredient, selecting appropriate excipients, or providing formulations that suit sensitive skin types.

The increasing awareness of the benefits of compounded medicines for skin conditions is further propelling the market. Patients who have not found adequate relief with standard commercial treatments are turning to compounded options to better manage their symptoms. Dermatologists are increasingly recommending compounded topical drugs for patients with chronic skin conditions, particularly those who have not responded well to traditional medications or those seeking more natural or combination therapies.

The rise in chronic skin conditions and the preference for personalized treatment options are key factors contributing to the growth of the compounded topical drug market. As more patients seek effective and tailored solutions, compounded topical drugs continue to gain prominence in dermatology practices worldwide.

Advancements in Compounding Technologies

Advancements in compounding technologies are a significant driver of the Global Compounded Topical Drug Market. The continuous improvements in compounding processes have led to enhanced precision, efficiency, and safety in the formulation of topical drugs. Automation in the compounding process has minimized the risks associated with human error, ensuring the consistency and quality of the final product. State-of-the-art equipment allows compounding pharmacies to mix active ingredients with greater accuracy, resulting in formulations that meet the specific needs of patients. This increased precision also leads to a reduction in errors that could lead to adverse reactions, improving patient safety and satisfaction.

Technological developments in ingredient sourcing and formulation have expanded the range of active ingredients available for inclusion in compounded topical drugs. Innovations such as microencapsulation and nanotechnology enable the delivery of ingredients in more effective ways, enhancing the bioavailability and stability of the active compounds. These technologies allow for better targeting of specific areas, such as skin conditions or localized pain, making compounded topicals more effective and faster acting.

Compounding technologies have also improved the scalability and efficiency of production, allowing compounding pharmacies to meet growing demand. Advanced inventory management systems, integrated digital tools, and precise formulation techniques enable pharmacies to quickly adjust to patient needs and prescription volumes. This technological evolution also supports the growth of personalized medicine, as compounding pharmacies can now produce customized topical formulations more swiftly and accurately.

These technological advancements help compounding pharmacies meet the increasing demand for personalized, effective, and safe topical treatments, making compounding an attractive option for healthcare providers and patients. This trend is expected to drive further growth in the compounded topical drug market in the coming years.

Increasing Focus on Preventive Healthcare

The increasing focus on preventive healthcare is significantly driving the Global Compounded Topical Drug Market. Preventive healthcare emphasizes maintaining health and preventing diseases before they develop. This shift has led to a growing demand for treatments that manage conditions early or provide relief from minor ailments before they escalate. Compounded topical drugs are essential in this preventive approach, allowing for tailored solutions to specific patient needs, promoting early intervention, and long-term health maintenance.

Topical drugs, applied directly to the skin, allow targeted treatment of conditions such as skin disorders, pain management, and chronic inflammation, all benefiting from early treatment. As healthcare consumers become more health-conscious, they seek non-invasive, localized solutions to manage symptoms or prevent conditions from worsening. This demand is particularly high in dermatology, where compounded topical drugs are used to treat skin conditions like eczema, psoriasis, and acne at early stages, before requiring more aggressive interventions.

The preventive healthcare approach aligns with the growing awareness of non-systemic treatments. Compounded topical drugs, delivering active ingredients directly to the affected area, minimize the risk of side effects commonly associated with oral medications or injections. As patients become more aware of the importance of self-care and proactive health steps, compounded topical solutions offer a convenient and effective way to manage symptoms and prevent chronic conditions' progression.

This increasing focus on preventive healthcare is creating a favorable environment for the compounded topical drug market's growth, as patients and healthcare providers prioritize personalized, proactive, and localized treatments. According to the Centers for Disease Control and Prevention (CDC), nearly 40% of all deaths in the United States are due to behavioral causes, highlighting the critical need for preventive healthcare measures.

Additionally, the CDC reports that optimal use of preventive care could add over 2 million healthy life-years to the U.S. population, underscoring the significant impact of preventive health strategies. These statistics emphasize the importance of preventive healthcare and the role of compounded topical drugs in addressing this need.

Key Market Challenges

Quality Control and Consistency

One of the key challenges in the Global Compounded Topical Drug Market is ensuring consistent quality control across compounded products. Compounding pharmacies are tasked with producing highly personalized treatments tailored to specific patient needs, which often involves complex formulations. Maintaining uniformity and high-quality standards throughout the compounding process is critical, as even minor variations in ingredient proportions or preparation methods can significantly affect the drug's efficacy and safety. Inconsistent quality can lead to poor therapeutic outcomes, patient dissatisfaction, and, in some cases, adverse reactions.

The variability in raw materials used in compounding poses another challenge. Unlike mass-produced drugs, compounded medications often rely on different suppliers for active ingredients and excipients. This variability can introduce discrepancies in drug strength, appearance, and stability. Additionally, the compounding process itself requires precise equipment and expert handling, as even slight deviations in temperature, mixing, or storage can affect the product's final quality.

Compounding pharmacies are required to adhere to strict standards set by regulatory bodies such as the U.S. Pharmacopeia (USP), but there is still a lack of uniform enforcement and oversight in some regions. This inconsistency in regulatory practices can create challenges in maintaining consistent quality control across the market. With the growing demand for compounded topical drugs, pharmacies must continuously invest in staff training, technology, and equipment to meet these quality control requirements.

The lack of centralized tracking and verification systems for compounded medications further complicates this issue. Without rigorous quality control mechanisms, there is a risk that substandard compounded drugs may reach patients, undermining trust in compounded therapies and negatively impacting the market's reputation.

High Cost of Compounded Medications

The high cost of compounded medications remains a significant challenge in the healthcare sector, presenting barriers to access for many patients. For instance, the Medicaid program reimburses pharmacies at a professional dispensing fee of USD 15.34 for compounded prescriptions, compared to USD 10.11 for standard medications. This reimbursement disparity highlights the complex nature of compounded medications, which are tailored to meet individual patient needs. The process involves sourcing specialty ingredients, often in small quantities, which are not as widely available as those used in mass-produced pharmaceuticals. Additionally, compounded medications require skilled professionals who must follow precise formulation guidelines, adding another layer of complexity and expense.

These factors contribute to the higher production costs associated with compounded medications, making them more expensive than traditional drugs. As a result, the increased costs are often passed on to patients, particularly in the form of out-of-pocket expenses. This becomes a significant issue for patients who do not have insurance coverage that extends to compounded medications, as they may be left with a financial burden that limits their ability to access necessary treatments. Even those with insurance may face higher co-pays or premiums, further restricting affordability.

The financial barrier created by the high costs of compounded medications can also discourage healthcare providers from prescribing them, opting instead for more affordable, mass-produced drugs that may not be as effective for certain patients. This trend creates a cycle of limited access to personalized treatments, despite the potential benefits compounded medications can offer in managing unique health conditions. Addressing the high cost of compounded medications through innovation, improved compounding techniques, and more equitable reimbursement policies will be essential to making these treatments more accessible and affordable for a wider range of patients.

Key Market Trends

Shift Towards Personalized Medicine

The shift towards personalized medicine is a major trend in the Global Compounded Topical Drug Market, reflecting a growing desire for tailored healthcare solutions. Traditional pharmaceutical products often provide a one-size-fits-all approach, which may not be effective for all patients, especially when dealing with chronic conditions or unique health needs. Compounded topical drugs offer a customized solution, allowing for adjustments in active ingredients, strength, and dosage based on individual patient requirements. This customization is particularly important in dermatology, pain management, and hormone therapy, where personalized treatments can significantly improve patient outcomes.

Personalized medicine in compounded topicals is gaining momentum as patients seek more effective and safer alternatives to conventional treatments. With an increasing understanding of how genetic, environmental, and lifestyle factors can impact an individual's response to medication, compounded topical drugs can be designed to suit specific health conditions. For instance, patients suffering from skin conditions such as eczema or psoriasis can receive compounded creams or ointments with combinations of active ingredients tailored to their specific skin type and severity of the condition.

This trend is also driven by a growing awareness of the limitations of mass-produced drugs, particularly in the management of conditions that require more than just standard treatment protocols. Personalized compounded medications offer flexibility, as physicians can work with compounding pharmacies to create formulations that align closely with a patient's unique medical history and needs. As a result, compounded topical drugs are seen as a more precise and effective alternative for patients, making personalized medicine an essential driver for growth in this market. The demand for tailored treatments is likely to continue expanding as both patients and healthcare providers increasingly embrace the benefits of personalized approaches to healthcare.

Increased Demand for Pain Management Solutions

The Global Compounded Topical Drug Market is experiencing significant growth, particularly in pain management solutions. This trend is largely driven by a growing awareness of the side effects and dependency risks associated with oral painkillers, especially opioids, and the desire for more localized, non-invasive treatments. Compounded topical drugs, which can be tailored to an individual's specific pain needs, offer a compelling alternative. These topical solutions allow for targeted relief, directly applying active ingredients such as analgesics, anti-inflammatories, and numbing agents to the site of pain, reducing the risk of systemic side effects.

Conditions like arthritis, neuropathic pain, sports injuries, and musculoskeletal disorders have seen a rise in compounded topical treatments. Topical creams, gels, and patches can deliver effective pain relief while avoiding the gastrointestinal issues or addictive risks often linked to oral pain medications. The ability to customize formulations also makes compounded topicals a preferred choice for patients who do not find relief with over-the-counter options. For example, combining various pain-relieving agents into a single compound can offer enhanced efficacy and a more holistic approach to pain management. In addition to addressing pain relief needs, compounded topicals provide an appealing alternative for those seeking natural or holistic ingredients. Many patients are turning to customized formulations that integrate natural substances, such as menthol, capsaicin, or herbal extracts, along with conventional pain-relieving compounds. The trend towards more personalized, targeted, and less invasive pain management solutions is fueling the growth of compounded topical drugs in the market, as patients look for safer, more effective ways to manage pain.

Recent data underscores the significant growth in the use of compounded topical pain medications. A survey of almost 500 patients found that 95% were satisfied with every aspect of their compounded therapy, except for the cost. The average out-of-pocket cost for compounded pain medications was reported to be USD 26. However, the average out-of-pocket cost for compounded prescriptions in general was USD 93, indicating that pain medications are more affordable compared to other compounded drugs. Despite the higher costs, the satisfaction rates suggest a strong preference for these personalized pain management solutions.

These statistics reflect a significant shift towards compounded topical pain management solutions, driven by patient satisfaction and increasing healthcare expenditures. The market's expansion is indicative of a broader trend towards personalized and effective pain management therapies.

Segmental Insights

Drug Type Insights

Based on the Drug Type, Pain Relief Topicals emerged as the dominant segment in the Global Compounded Topical Drug Market in 2024. This is due to the increasing demand for non-invasive and localized pain management solutions. As the opioid crisis continues to raise awareness of the dangers associated with oral painkillers, patients are turning to alternatives that offer targeted relief without the systemic side effects. Pain relief topicals, such as creams, gels, and patches, are formulated to deliver active ingredients directly to the site of pain, offering faster and more efficient relief for conditions like arthritis, neuropathic pain, and sports injuries. The customization aspect of compounded pain relief topicals also plays a significant role in their dominance. These topicals can be tailored to suit individual patient needs by combining various pain-relieving agents, enhancing efficacy. This level of personalization is especially beneficial for patients who do not find relief with standard over-the-counter products or have specific sensitivities to certain ingredients. Moreover, the rising preference for natural and holistic pain management options, such as topicals containing menthol or capsaicin, further fuels the growth of this segment. As patients increasingly seek effective, safer, and personalized pain management solutions, the demand for compounded pain relief topicals is expected to continue growing, solidifying their dominance in the market.

End User Insights

Based on the End User, Hospitals and Clinics emerged as the dominant segment in the Global Compounded Topical Drug Market in 2024. This dominance is due to the increasing reliance on healthcare institutions for personalized and effective treatments. These facilities are at the forefront of patient care, offering customized solutions for a wide range of medical conditions, including pain management, skin disorders, and dermatological issues. Compounded topical drugs, which are tailored to individual patient needs, play a crucial role in providing specialized care in hospitals and clinics. They enable healthcare providers to address specific patient requirements that may not be met by mass-produced, commercially available products. Hospitals and clinics are equipped with the expertise and resources to compound these drugs under strict quality control standards, ensuring their safety and efficacy. The growing adoption of compounded therapies in these settings is driven by the need for personalized medicine, particularly in treating complex conditions or patients with unique medical needs. Additionally, healthcare providers are increasingly turning to compounded topicals to minimize the use of oral medications, offering localized treatments that reduce systemic side effects. As hospitals and clinics continue to prioritize patient-centered care, the demand for compounded topical drugs is expected to remain strong, further cementing their role as the dominant end user in the market.

Regional Insights

North America emerged as the dominant region in the Global Compounded Topical Drug Market in 2024. This is primarily due to several key factors, including a strong healthcare infrastructure, high demand for personalized treatments, and increasing awareness of the benefits of compounded medications. The U.S. in particular has a well-established healthcare system with a high prevalence of conditions that require compounded treatments, such as chronic pain, dermatological disorders, and hormonal imbalances. Patients in North America are increasingly seeking alternatives to traditional pharmaceuticals, turning to compounded topical drugs for their ability to provide customized solutions tailored to individual needs. The regulatory environment in North America, particularly the U.S. Food and Drug Administration (FDA) and state pharmacy boards, supports the growth of the compounded drug market by ensuring the safety and efficacy of compounded products, thereby fostering patient confidence. Additionally, a rise in the number of compounding pharmacies offering specialized services to healthcare providers has further fueled market growth. With growing concerns over the side effects of oral medications, patients are opting for topical alternatives to manage pain and other chronic conditions more effectively. As healthcare trends continue to shift towards personalized medicine and non-invasive treatments, North America's dominance in the compounded topical drug market is expected to persist in the coming years.

Key Market Players

• Fresenius Kabi AG
• B. Braun SE
• Hisamitsu Pharmaceutical Co., Inc.
• Glenmark Pharmaceuticals Ltd.
• Optum Inc.
• Nephron Pharmaceuticals Corporation
• Sun Pharmaceutical Industries Ltd.
• Central Admixture Pharmacy Services, Inc.
• CareFirst Specialty Pharmacy
• Medisca Inc.

Report Scope:

In this report, the Global Compounded Topical Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounded Topical Drug Market, By Drug Type:

• Hormonal Topicals
• Pain Relief Topicals
• Antifungal and Antibacterial Topicals
• Dermatological Topicals
• Wound Healing
• Others

Compounded Topical Drug Market, By Therapeutic Area:

• Pain Management
• Skin Disorders and Dermatology
• Hormonal Therapy
• Infections
• Others

Compounded Topical Drug Market, By End User:

• Hospitals and Clinics
• Pharmacies and Retail Drug Stores
• Homecare Settings
• Others

Compounded Topical Drug Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Compounded Topical Drug Market.

Available Customizations:

Global Compounded Topical Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Compounded Topical Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Hormonal Topicals, Pain Relief Topicals, Antifungal and Antibacterial Topicals, Dermatological Topicals, Wound Healing, Others)
  • 5.2.2. By Therapeutic Area (Pain Management, Skin Disorders and Dermatology, Hormonal Therapy, Infections, Others)
  • 5.2.3. By End User (Hospitals and Clinics, Pharmacies and Retail Drug Stores, Homecare Settings, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Compounded Topical Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Compounded Topical Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Compounded Topical Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Compounded Topical Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Compounded Topical Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Compounded Topical Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Compounded Topical Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Compounded Topical Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Compounded Topical Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Compounded Topical Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia-Pacific Compounded Topical Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Compounded Topical Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Compounded Topical Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Compounded Topical Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Compounded Topical Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Compounded Topical Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. South America Compounded Topical Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Compounded Topical Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Compounded Topical Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Compounded Topical Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. Middle East and Africa Compounded Topical Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Compounded Topical Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Compounded Topical Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Compounded Topical Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Fresenius Kabi AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. B. Braun SE
• 14.3. Hisamitsu Pharmaceutical Co., Inc.
• 14.4. Glenmark Pharmaceuticals Ltd.
• 14.5. Optum Inc.
• 14.6. Nephron Pharmaceuticals Corporation
• 14.7. Sun Pharmaceutical Industries Ltd.
• 14.8. Central Admixture Pharmacy Services, Inc.
• 14.9. CareFirst Specialty Pharmacy
• 14.10. Medisca Inc.

15. Strategic Recommendations

16. About Us & Disclaimer